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FIG. 1. Differential effects of arachidonic acid on glutamate-
induced currents recorded in voltage-clamped uninjected oo-
cytes (control) and oocytes injected with RNA transcribed from 
human EAA T cDNAs. Cells were clamped at -60 m V, and compounds 
were superfused for the times indicated by open (30 f.LM L-glutamate) 
and closed (100 f.LM arachidonic acid) bars. Identical results were seen in 
batches of oocytes from five frogs. 
a rapid onset and reversed slowly upon washout of arachido-
nate (Fig. 1). These effects were due to specific interaction with 
the transporters, as application of arachidonate alone or with 
glutamate did not induce a current in uninjected oocytes (Fig. 
1). In addition, arachidonate alone did not induce any current 
in oocytes expressing the transporters nor were the glutamate 
transport currents altered by co-application of vehicle (0.1% 
dimethyl sulfoxide) with glutamate (not shown). In order to 
determine whether the arachidonate-induced changes in trans-
port currents mediated by EAAT1 and EAAT2 resulted from 
changes in glutamate uptake, measurements were made of 
radiolabeled L-glutamate transport mediated by these sub-
types. Uptake of 10 J.LM L-[3H]glutamate into oocytes expressing 
the transporters was linear for at least 20 min and was in-
creased 10-100-fold over control (uninjected or water-injected) 
oocytes. In agreement with voltage clamp measurements, ad-
dition of arachidonic acid (100 J.LM) resulted in differential ef-
fects on the transporters (Fig. 2). Specific uptake in oocytes 
expressing EAAT1 was decreased from 275 ::+:: 9 to 210 ::+:: 10 
fmol/oocyte/s (mean ::+:: S.E. n = 6). In contrast, uptake in 
oocytes expressing EAAT2 was increased from 75 ::+:: 6 to 143 ::+:: 
11 fmol/oocyte/s (n = 6; Fig. 2). Similar effects were seen in 
measurements of 10 J.LM L-raHJglutamate into the human em-
bryonic kidney cell line HEK-293 stably transfected with 
EAAT1 or EAAT2. Co-application of 100 J.LM arachidonate re-
duced EAAT1-mediated uptake from 158 ::+:: 8 to 123 ::+:: 9 pmoll 
105 cells (n = 6), while uptake of L-[3 H]glutamate mediated by 
EAAT2 was increased from 120 ::+:: 6 to 175 ::+:: 6 pmol/105 cells (n 
= 6). The background in control (non-transfected) cells was not 
significantly changed by addition of arachidonate (10.9 ::+:: 1.0 
control versus 9.9 ::+:: 1.0 pmol/105 cells; n = 6). 
The effects of arachidonate on transport in oocytes expressing 
EAAT1 and EAAT2 were dose-dependent and saturable. The K 0 .5 
for the maximal inhibition of the EAAT1 current was 16 ::+:: 6 J.LM, 
while the K 0 .5 for maximal increase of the EAAT2 current was 59 
::+:: 6 !JM (n = 5; Fig. 3, A and B). The kinetic mechanism under-
lying the modulation oftransport was investigated by analyzing 
the effect of arachidonic acid on the glutamate concentration 
response. Co-application of 100 J.LM arachidonic acid with varying 
doses of glutamate to oocytes expressing EAAT1 resulted in a 29 
::+:: 1% decrease in the maximal current relative to control, while 
the apparent affinity for glutamate was not significantly altered 
(Km = 42 ::+:: 3 versus 37 ::+:: 1 J.LM, n = 5; Fig. 4A). In contrast, the 
EAAT2 transport currents were enhanced via a decrease in the 
transport affinity constant for glutamate from 36 ::+:: 7 to 14 ::+:: 1 
J.LM (n = 5; Fig. 4B). 
The pharmacological mechanism of action of arachidonic acid 
was investigated by testing structural analogues and inhibitors 
of its metabolism. The increase in EAAT2-mediated transport 
of 10 J.LM L-glutamate caused by 100 J.LM arachidonic acid was 
¥ 0.3 
"' ~ 0.25 
e 0.2 
~ 
~ 0.15 
::J 0.1 
~ 0.05 
l 0 
0 + 0 + 0 + 
EAAT1 EAAT2 control 
FIG. 2. Arachidonic acid inhibits uptake of L-[3H]glutamate 
into oocytes expressing EAATI and stimulates uptake mediated 
by EAAT2. Uptake in control (uninjected) oocytes was unaffected by 
arachidonic acid. 
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FIG. 3. Concentration response for arachidonic acid effects on 
glutamate transport currents mediated by EAATI (A) and 
EAAT2 (B). The percentage decrease or increase was calculated by 
comparing the current amplitudes induced by 30 f.LM L-glutamate co-
applied with varying concentrations of arachidonic acid to the control 
transport current amplitudes in response to 30 f.LM L-glutamate in the 
same oocytes. Data points represent mean :!: S.E. (n = 3-4). 
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FIG. 4. Differential effects of arachidonic acid on transport 
kinetic parameters for EAATI (A) and EAAT2 (B). Data points 
representing normalized mean :!: S.E. for 5 oocytes were fit to I = 
Im.,/[Glu)/([Glu) + Km). A, co-application of 100 f.LM arachidonic acid 
reduced the maximal EAATl current 29 :!: 1% without significantly 
changing the apparent affinity for glutamate. B, glutamate concentra-
tion dependence of EAAT2 transport currents was shifted by 100 f.LM 
arachidonic acid from 36 :!: 7 to 14 :!: 1 JLM without significantly affect-
ing the !max• 
compared with equal concentrations of linolenic, linoleic, or 
arachidic acid. The order of efficacy relative to arachidonic acid 
was linolenic acid (91 ::+:: 21%) > linoleic acid (49 ::+:: 9%) ll> 
arachidic acid (1 ::+:: 5%; n = 3). The same rank order of efficacy 
relative to arachidonic acid was observed for inhibition of 
EAAT1: linolenic (109 ::+:: 19%) >linoleic (43 ::+:: 14%) ll> arachidic 
(5 ::+:: 5%; n = 3). Neither the cyclooxygenase inhibitor indo-
methacin (100 J.LM) nor the lipoxygenase inhibitor nordihy-
droguaritic acid (50 J.LM) affected arachidonate inhibition of 
EAAT1 (n = 3) or stimulation of EAAT2 (n = 6). These results, 
together with the rapid onset of modulation (Fig. 1), suggest 
that both effects on glutamate transport are mediated directly 
by arachidonic acid itself, rather than via a metabolite. 
DISCUSSION 
Arachidonic acid has been proposed to be a messenger mol-
ecule that influences synaptic transmission released by synap-
tic activation of ionotropic and metabotropic glutamate recep-
tors (8, 9). Its release also occurs following ischemia (10, 11). 
Arachidonic acid-mediated inhibition, but not stimulation, of 
glutamate transport has been reported previously (13-16). 
Similar to the results in the present study, these inhibitory 
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actions appear to be mediated by arachidonic acid itself, as are 
its potentiating actions on synaptic transmission in hippocam-
pus (12). Although net L-[3H]glutamate uptake into rat brain 
synaptosomes and slices is reduced by arachidonic acid (13-15), 
regional heterogeneity in transporter expression would not be 
resolved in such an assay (6, 7). EAAT1 is relatively abundant 
in many human brain regions, particularly in cerebellum, 
while EAAT2 is highly abundant in forebrain and midbrain 
regions including cortex and basal ganglia (6). EAAT3 is uni-
formly expressed in brain and periphery at lower levels (6). 
These distributions are consistent with the immunohistochem-
icallocalization in rat brain of the analogous glutamate trans-
porters with which they share >90% sequence identities (7). 
The glutamate receptor-mediated stimulation of arachido-
nate synthesis in glial cells (17) and neurons (8, 9, 18) suggests 
that arachidonic acid could modulate uptake in both cell types 
according to which transporter subtype is expressed. In one 
well defined system, the salamander retinal Mueller cell, 
arachidonic acid directly inhibits glutamate transport currents 
(16). In accord with this result, a transcript encoding a gluta-
mate transporter homologous to EAAT1 is highly abundant in 
these cells, and expression of this salamander transporter in 
Xenopus oocytes confirms that it is negatively modulated by 
arachidonate.2 While some studies on cultured mammalian 
glial cells have demonstrated arachidonic acid inhibition of 
glutamate uptake (15, 19), a recent study utilizing cultured 
astroglial cells demonstrated that inhibition of arachidonic acid 
synthesis during ischemia potentiates toxicity, suggesting a 
possible neuroprotective action of arachidonic acid (20). 
The present results suggest the possibility that arachidonic 
acid could differentially influence the rate of clearance of syn-
aptically released glutamate, which can in turn influence the 
kinetics of glutamatergic transmission at some synapses (21, 
22). Moreover, modulation of interstitial glutamate levels could 
lead to changes in synaptic efficacy by tonic activation of re-
ceptors (23) or receptor desensitization (24). The actions of 
2 N. Zerangue, J. Arriza, S. Amara, and M. Kavanaugh, unpublished 
results. 
arachidonic acid on glutamate transport kinetics would allow 
for complex regulation of synaptic transmission as well as 
excitotoxicity via either positive or negative feedback according 
to which transporter subtypes are present in a particular 
pathway. 
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